| Literature DB >> 34946129 |
Mylene Gorzynski1,2, Tiana Week1,3, Tiana Jaramillo1,4, Elizaveta Dzalamidze1,5, Lia Danelishvili1.
Abstract
Mycobacterium abscessus subsp. abscessus (MAB) is a fast-growing nontuberculous mycobacterium causing pulmonary infections in immunocompromised and immunocompetent individuals. The treatment of MAB infections in clinics is extremely challenging, as this organism is naturally resistant to most available antibiotics. There is limited knowledge on the mechanisms of MAB intrinsic resistance and on the genes that are involved in the tolerance to antimicrobials. To identify the MAB genetic factors, including the components of the cell surface transport systems related to the efflux pumps, major known elements contributing to antibiotic resistance, we screened the MAB transposon library of 2000 gene knockout mutants. The library was exposed at either minimal inhibitory (MIC) or bactericidal concentrations (BC) of amikacin, clarithromycin, or cefoxitin, and MAB susceptibility was determined through the optical density. The 98 susceptible and 36 resistant mutants that exhibited sensitivity below the MIC and resistance to BC, respectively, to all three drugs were sequenced, and 16 mutants were found to belong to surface transport systems, such as the efflux pumps, porins, and carrier membrane enzymes associated with different types of molecule transport. To establish the relevance of the identified transport systems to antibiotic tolerance, the gene expression levels of the export related genes were evaluated in nine MAB clinical isolates in the presence or absence of antibiotics. The selected mutants were also evaluated for their ability to form biofilms and for their intracellular survival in human macrophages. In this study, we identified numerous MAB genes that play an important role in the intrinsic mechanisms to antimicrobials and further demonstrated that, by targeting components of the drug efflux system, we can significantly increase the efficacy of the current antibiotics.Entities:
Keywords: M. abscessus; antibiotic treatment; biofilm; efflux pumps; intrinsic resistance; macrophage; rapidly growing mycobacteria; virulence factors
Year: 2021 PMID: 34946129 PMCID: PMC8707978 DOI: 10.3390/microorganisms9122527
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Antibiotic concentrations used in the MAB mutant library susceptibility testing.
| Antibiotic | MAB 19977 | |
|---|---|---|
| MIC (μg/mL) | BC (μg/mL) | |
| AMK | <16 | 32 |
| CLA | <2 | 8 |
| FOX | <16 | 128 |
AMK: amikacin, CLA: clarithromycin, and FOX: cefoxitin.
Primers used in this study for the qRT-PCR analysis of the transport genes in the MAB clinical isolates.
| MAB Gene | Sequence (5′-3′) | Sequence (5′-3′) |
|---|---|---|
|
| CTCGCCAACGCGAGTAATTC | CAGCCCAGCTGATAACCCAT |
|
| ATCAGTGATGTCGCCAAGGG | AGCGTCAACAGAACGACGAT |
|
| GTGATATCGCTGCTCGGTGA | CGCGACGATGAAAATCGCAT |
|
| CTGTGATTGGGGCGCTATTG | TTCTTCGTCTTAGCCGCCG |
|
| GCCAACGCATCCAAACCTAC | GATTCTGCGGTAGAGCCGAT |
|
| TGGGGAATTCGTTACGCGAG | CCACGCCAACTTCACAAAGG |
|
| CTCGACTACGAGGGGAAAGC | GGTCGTCCATTTGTCACCGA |
|
| GAGATTCGTCTCGGCGATCA | GTCAGATGGGGAAACAGCGA |
|
| GGGCTCACCTACTCCTCGTA | TTGGTTCTCCGACTTGGTGG |
|
| AGGGTTCAGTCACGCATTGT | GTAACGCCCGTCGATCATCT |
|
| GGAGCTACGCACACCAAAGA | GCGATTCAGCACTTCCCTGA |
|
| GACCACCCGCAATGTACAGA | TGCATGATGGTTCCGGTTGA |
|
| CTCCACGGCGTATTCGGTAA | ACAGCGGATCACCATTGACA |
|
| AATCTGACTGTGCACCAGGG | ATCAGCTCACCGTCGATACG |
|
| TGCGATAGACGACGTACTGC | CAATGGACCGGTGATGGTGA |
|
| ATGTCGAAATGCGATGGGGT | GCCGATAACACTACGGGTCC |
| 16S | GGCTAACCATCCGTCTCTGG | CGGAAGAAAGTCGTCGGTCA |
Figure 1A pie chart displays MAB 19977 transposon mutants identified in this study that are grouped based on the protein functional classes. The gene knockout mutants were sequenced with LM-PCR, and transposon insertions were analyzed by blasting obtained nucleotide sequences (adjacent to the transposon) against the reference genome of MAB 19977. The gene domains/motifs of the putative proteins were analyzed using the CD-Search tool available at NCBI and by aligning proteins to the well-characterized genome of M. tuberculosis H37Rv.
The selected MAB 19977 gene knockout mutants of cell wall transport systems associated with an increased (BC) or decreased (MIC) susceptibility to antibiotics.
| Gene | Function | Conserved Domain/Notes | MIC/BC |
|---|---|---|---|
|
| MspA membrane porin | Contains a signal peptide | BC |
|
| MmpL membrane drug exporter protein | Transport protein with a role in drug resistance | MIC |
|
| Putative MmpL membrane protein | Possible role in drug resistance | MIC |
|
| Putative membrane transporter protein. | TauE, sulfite exporter. Integral membrane protein involved in the transport of anions across the cytoplasmic membrane during taurine metabolism as an exporter of sulfoacetate. | MIC |
|
| Conserved hypothetical protein | Integral membrane transporter protein | MIC |
|
| Diguanylate cyclase/phosphodiesterase | GGDEF Diguanylate-cyclase/ABC2_membrane superfamily regulates cell surface adhesion in bacteria/ABC-2-type transporter | MIC |
|
| Hypothetical protein | PknH_C-like extracellular domain | BC |
|
| Molybdenum ABC transporter ModC, ATP-binding protein | P-loop_NTPase superfamily | MIC |
|
| Probable molybdenum ABC transporter, periplasmic | Periplasmic-binding protein type 2 superfamily | MIC |
|
| Putative ABC transporter, ATP-binding protein | ModF ABC-type molybdenum transport system | MIC |
|
| Putative sulfate transporter/anti-Sigma factor | MIC | |
|
| Conserved hypothetical protein | ABC_6TM_exporters superfamily: Six-transmembrane helical domain of an uncharacterized ABC exporter | MIC |
|
| Putative membrane protein | MmpS family protein with a potential role in the transport of MmpL substrates | BC |
|
| Putative amino acid ABC transporter, ATP-binding protein | GlnQ | MIC |
|
| Probable non-ribosomal peptide synthetase PstA | Sulfate Transporter and anti-Sigma factor antagonist | MIC |
|
| Hypothetical protein | PknH_C-like extracellular domain | BC |
MIC: minimal inhibitory concentration; BC: bactericidal concentration.
The antibiotic susceptibility of MAB gene knockout mutants associated with the surface transport systems and MAB clinical isolates.
| Bacterial ID | MIC for Broth Dilution in 7H9 (μg/mL) | |||
|---|---|---|---|---|
| AMK | CLA | FOX | ||
|
|
| 6 | 0.5 | 4 |
|
| 6 | 0.5 | 4 | |
|
| 12 | 0.5 | 16 | |
|
| 16 | 0.5 | 4 | |
|
| 12 | 0.5 | 8 | |
|
| 10 | 0.5 | 16 | |
|
| 10 | 2 | 4 | |
|
| 10 | 0.5 | 16 | |
|
| 10 | 2 | 16 | |
|
| 10 | 0.5 | 4 | |
|
| 10 | 2 | 8 | |
|
| 10 | 0.5 | 4 | |
|
|
| 128 | 8 | 32 |
|
| 128 | 4 | 32 | |
|
| 64 | 4 | 32 | |
|
| 128 | 8 | 32 | |
|
| MAB 19977 | 16 | 2 | 16 |
| NR 49093 strain DJO 44274 | >256 | >32 | 16 | |
| NR 44273 strain 4529 | >128 | >32 | 16 | |
| NR 44273 strain 4529 | 16 | 4 | 16 | |
| DNA00703 | 16 | 4 | 32 | |
| DNA01163 | 16 | 4 | 32 | |
| DNA01627 | 16 | 16 | 32 | |
| DNA01715 | 16 | 4 | 32 | |
| DNA01639 | 16 | 2 | 32 | |
Figure 2The percentage of biofilm mass for MAB mutants belonging to the surface transport systems. The biofilm mass of the MAB wild-type and transposon mutants were quantified at day 7 with 0.1% crystal violet staining and solubilization of 30% acetic acid, and the measurements were recorded at OD570. The percentage of biofilm formation was normalized to the positive control, representing the MAB 19977 biofilm mass in SCFM (dashed red line), while the MAB 19977 biofilm mass in HBSS represents the negative control. Data represents the mean SD of wells assayed in duplicate and with three biological replicates. Significant differences were observed between the positive biofilm of MAB 19977 in SCFM and the negative control in HBSS (* p < 0.05), MAB_1171c (** p < 0.01), MAB_2787c (* p < 0.05), and MAB_4036 (* p < 0.05).
Figure 3The intracellular survival of MAB mutants associated with surface transport systems. The THP-1 monocytes were differentiated with 20-ng/mL PMA in 96-well plates and rested for 3 days to form confluent monolayers. The macrophages were then infected with one of 15 mutants or the wild-type MAB 19977 (control) at a MOI of 1:1. While an infection rate was measured at 1 h (A), the survival rates were determined at 5 days post-infection (B) by lysing cells with 0.1% Triton X100 and plating lysates on 7H10 agar plates for viable bacterial CFU/well counts.
Figure 4The fold changes in the efflux pump and ABC transporter gene expressions in the clinical isolates of MAB exposed to AMK. Each clinical strain at 3 × 108 CFU/mL was matched to the McFarland Standard 1.0 and inoculated with 1× MIC of AMK. The RNAs were extracted after 8 h, and the DNase was treated and used for cDNA synthesis, as described in the Materials and Methods. The gene expressions were evaluated with qRT-PCR. (A) MAB_0937c, MmpL drug efflux pump; (B) MAB_1137c, MmpL efflux pump; (C) MAB_4117c, efflux pump related MmpS; (D) MAB_4237c encodes for an ABC transporter.
Figure 5The improved antibiotic efficacy against infections of MAB efflux pump-deficient mutants in THP-1 macrophages. (A) The intracellular growth dynamics of MAB_0937cΔ and MAB_1137cΔ gene knockout mutants and MAB_0937c(+) and MAB_1137c(+) complemented clones without AMK treatment in comparison to the wild-type MAB 19977 were recorded with CFU/mL counts over 5 days of infection and by lysing THP-1 cells at the 1-h, 24-h, 72-h, and 120-h time points. (B) Intracellular survival rates of gene knockout and complemented clones during AMK treatment measured with viable bacterial CFU counts at 1 h, 24 h, 72 h, and 120 h post-infection. Data represent the mean ± SD of two independent experiments, each completed in triplicate. * p < 0.05 and ** p < 0.01 between the complemented clone and mutant at the corresponding time points.